Recent Company News

• 07:14 AM ET Jun 11, 2026
  

  Takeda Pharmaceutical's zasocitinib outperforms deucravacitinib in Head-to-Head Phase 3 Psoriasis Study (¥5033.0000, 0)

• 04:34 PM ET Jun 09, 2026
  

  FDA accepts Takeda's sBLA for Intravenous ENTYVIO (vedolizumab) in pediatric Ulcerative Colitis and Crohn's Disease (¥4975.0000, 0)

• 03:12 AM ET Jun 05, 2026
  

  Takeda Pharmaceutical updates Q4 and FY results to reflect impact of verdict in AMITIZA trial (¥4926.0000, 0)

• 01:44 PM ET Jun 03, 2026
  

  Transcript Intelligence : Takeda Pharmaceutical à la conférence Jefferies Global Healthcare

• 01:44 PM ET Jun 03, 2026
  

  Transcript Intelligence: Takeda Pharmaceutical at Jefferies Global Healthcare Conference

• 08:06 PM ET May 31, 2026
  

  Innovent Biologics presents preliminary PoC data of IBI363 at ASCO (HK$83.35, 0.00)

• 07:39 PM ET May 31, 2026
  

  Ascentage Pharma presents data on alrizomadlin and olverembatinib at ASCO 2026 (HK$39.24, 0.00)

• 12:09 PM ET May 30, 2026
  

  Mirum Pharmaceuticals announces new data from rare liver disease programs presented at the EASL International Liver Congress 2026 ($101.50, 0.00)

• 10:06 AM ET May 30, 2026
  

  Exelixis announces results from subgroup analysis of phase 3 cabinet pivotal trial evaluating CABOMETYX (cabozantinib) in non-functional and functional neuroendocrine tumors at ASCO 2026 ($50.48, 0.00)

• 12:13 PM ET May 22, 2026
  

  OpenAI prevails at trial, clearing way for IPO; attacks continue on proxy advisors for ESG practices in litigation themes (22-May)